reboxetine has been researched along with mianserin in 23 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (mianserin) | Trials (mianserin) | Recent Studies (post-2010) (mianserin) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 2,624 | 539 | 488 |
| Protein | Taxonomy | reboxetine (IC50) | mianserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 1.4125 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.0012 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 1.4125 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.163 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 1.078 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 2.066 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.3981 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 1.9 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.32 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0213 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.423 | |
| D(2) dopamine receptor | Homo sapiens (human) | 7.0795 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.38 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0661 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.872 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.21 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 1.405 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.543 | |
| D(4) dopamine receptor | Homo sapiens (human) | 3.3113 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.21 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.21 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.38 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.163 | |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | 1.4125 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.008 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.083 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.1148 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.3802 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.011 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0043 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.872 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.068 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 2.9 | |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | 0.1148 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.4074 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.21 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0024 | |
| D(3) dopamine receptor | Homo sapiens (human) | 3.8905 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0073 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.19 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 1.4125 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 0.88 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.085 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 3.5481 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 1.4125 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 1.4125 | |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | 1.4125 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (73.91) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Gorman, JM; Sullivan, G | 1 |
| Fava, M | 1 |
| Kent, JM | 1 |
| Cohen, NL; Kennedy, SH; Lam, RW; Wan, DD | 1 |
| Aguglia, E; Amore, M; Delgado, PL; Gastpar, M; Hawley, C; Hirschfeld, RM; Kasper, S; Linden, M; Massana, J; Mendlewicz, J; Möller, HJ; Montgomery, SA; Nemeroff, CB; Saiz, J; Such, P; Torta, R; Versiani, M | 1 |
| Elger, CE; Falkai, P; Kühn, KU; Maier, W; Quednow, BB; Thiel, M | 1 |
| Baghai, T; Laakmann, G; Schüle, C | 1 |
| Di Chiara, G; Frau, R; Valentini, V | 1 |
| Alamo, C; López-Muñoz, F; Rubio, G; San, L | 1 |
| Almási, J; Rihmer, Z | 1 |
| Baumann, P; Engel, R; Fähndrich, E; Greil, W; Hippius, H; Horvath, A; Mayland, G; Rüther, E; Schmidt, LG; Zullino, D | 1 |
| Amann, B; Hegerl, U; Juckel, G; Mergl, R; Mulert, C; Padberg, F; Pogarell, O; Sterr, A | 1 |
| Baghai, TC; Buechs, R; Eser, D; Jordan, M; Rupprecht, R; Schüle, C; Zwanzger, P | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Källén, B; Lennestål, R | 1 |
| Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ | 1 |
| Brunnauer, A; David, I; Fric, M; Hermisson, I; Laux, G; Möller, HJ | 1 |
| Bellodi, L; Calati, R; Chiesa, A; De Ronchi, D; Perna, G; Serretti, A | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Artigas, F; Bortolozzi, A; Castañé, A; Masana, M; Santana, N | 1 |
| Callado, LF; Díez-Alarcia, R; González-Maeso, J; Meana, JJ; Miranda-Azpiazu, P; Morentin, B; Muguruza, C | 1 |
| Chmielarz, P; Chorązka, K; Kowalska, M; Kuśmierczyk, J; Nalepa, I; Rafa-Zabłocka, K; Satała, G | 1 |
| Keidan, L; Pick, CG; Schreiber, S | 1 |
7 review(s) available for reboxetine and mianserin
| Article | Year |
|---|---|
Noradrenergic approaches to antidepressant therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Mianserin; Mirtazapine; Morpholines; Norepinephrine; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors | 2000 |
New approaches to the treatment of refractory depression.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Pindolol; Piperazines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Triazoles; Triiodothyronine | 2000 |
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Morpholines; Piperazines; Reboxetine; Structure-Activity Relationship; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2000 |
Combining antidepressants for treatment-resistant depression: a review.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Humans; Mianserin; Monoamine Oxidase Inhibitors; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
Topics: Antidepressive Agents; Congresses as Topic; Cyclopropanes; Decision Trees; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lithium; Mianserin; Milnacipran; Mirtazapine; Morpholines; Practice Patterns, Physicians'; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Novel antidepressants and panic disorder: evidence beyond current guidelines.
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclopropanes; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Morpholines; Panic Disorder; Practice Guidelines as Topic; Reboxetine; Thiophenes | 2011 |
6 trial(s) available for reboxetine and mianserin
| Article | Year |
|---|---|
Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants.
Topics: Adult; Aged; Analysis of Variance; Anticonvulsants; Antidepressive Agents; Chi-Square Distribution; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Electroencephalography; Epilepsy, Temporal Lobe; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Patient Dropouts; Personality Inventory; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Time Factors | 2003 |
Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Adrenocorticotropic Hormone; Adult; Area Under Curve; Drug Combinations; Drug Interactions; Growth Hormone; Humans; Hydrocortisone; Male; Mianserin; Mirtazapine; Morpholines; Prolactin; Reboxetine; Time Factors | 2004 |
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Dysthymic Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents; Corticotropin-Releasing Hormone; Depressive Disorder, Major; Dexamethasone; Female; Glucocorticoids; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Pituitary-Adrenal System; Psychiatric Status Rating Scales; Reboxetine; Time Factors | 2006 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention; Automobile Driving; Computer Simulation; Depressive Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Psychomotor Performance; Reaction Time; Reboxetine | 2008 |
10 other study(ies) available for reboxetine and mianserin
| Article | Year |
|---|---|
Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine.
Topics: Analysis of Variance; Animals; Cerebral Cortex; Clozapine; Desipramine; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Extracellular Space; Male; Mianserin; Microdialysis; Morpholines; Neural Pathways; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Piperazines; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin Antagonists; Symporters; Time Factors | 2004 |
Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Community Mental Health Centers; Drug Prescriptions; Drug Utilization; Female; Germany; Hospitals, Psychiatric; Humans; Mental Disorders; Mianserin; Middle Aged; Mirtazapine; Morpholines; Piperazines; Practice Patterns, Physicians'; Reboxetine; Rural Health Services; Selective Serotonin Reuptake Inhibitors; Sex Factors; Switzerland; Triazoles; Urban Health Services | 2005 |
Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Electroencephalography; Epilepsy; Female; Humans; Male; Mental Disorders; Mianserin; Middle Aged; Mirtazapine; Morpholines; Reboxetine; Venlafaxine Hydrochloride | 2006 |
Delivery outcome in relation to maternal use of some recently introduced antidepressants.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adrenergic Uptake Inhibitors; Antidepressive Agents; Birth Weight; Cyclohexanols; Databases, Factual; Delivery, Obstetric; Female; Gestational Age; Humans; Infant Mortality; Infant, Newborn; Mianserin; Mirtazapine; Morpholines; Pregnancy; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects; Reboxetine; Registries; Selective Serotonin Reuptake Inhibitors; Smoking; Sweden; Venlafaxine Hydrochloride | 2007 |
Restless legs syndrome as side effect of second generation antidepressants.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Prospective Studies; Reboxetine; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors | 2008 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Brain-Derived Neurotrophic Factor; Depression; Dopamine; Drug Synergism; Drug Therapy, Combination; Extracellular Fluid; Gene Expression Regulation; Male; Mianserin; Mirtazapine; Morpholines; Organ Specificity; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Reboxetine; RNA, Messenger | 2012 |
Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment.
Topics: Amino Acids; Animals; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Down-Regulation; Female; Humans; Ketanserin; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Prefrontal Cortex; Radioligand Assay; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT2A; Receptors, Metabotropic Glutamate; RNA, Messenger; Tritium; Xanthenes | 2014 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Regulation; Humans; Imipramine; Mianserin; Mice; PC12 Cells; Rats; Reboxetine; Receptors, Adrenergic, alpha-1; Signal Transduction | 2021 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride | 2023 |